The abstract is read at the publisher; the summary is JClub's.
A European expert consensus identifies 11 decision-critical topics for managing new biologic therapies in myasthenia gravis, addressing patient selection and long-term strategy amid uneven access.
- Why it matters: New complement-inhibiting and neonatal Fc-receptor–blocking treatments are now standard, but clinicians face uncertainty about who benefits, how to judge response, and how to sequence care across different European systems.
- What they did: A panel of adult and pediatric neurologists plus patient representatives performed a literature review of pivotal trials and real-world evidence, then built consensus statements for 11 topics using a modified Delphi process.
- The result: The position paper offers adaptable guidance for clinicians on assessment, serology, switching, predictors, concomitant therapy management, discontinuation, ocular applicability, and future trial directions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.